Focusing on adiponectin led Dr. Medina's lab to protein kinase A or «PKA» — a protein that, when activated by adiponectin, suppresses the fatty acids that
myeloma cells need, leading to their demise.
Whether investigating fat
cells, immunotherapy or use of the CRISPR - Cas 9 gene - editing tool, which a federal panel recently approved for a select number of patients suffering from three types of cancers, including multiple
myeloma, approaches beyond attacking cancer
cells are
needed in the fight against many cancers.